subject: Foreign Pharmaceutical Industry Looking For Their Breakthrough Anchaoyongdong [print this page] Although the market growth slows growing, but not quiet the pharmaceutical industry: the quadrennial U.S. presidential election will reshape political situation, thereby changing the world's largest Pharmaceutical market Section of the development process; in the east, impressive is the ever-changing, from China, India and other emerging system Pharmaceutical companies Industry began more integration into the world arena ... ...
New research and development collaboration between government and enterprises honeymoon
2007 12 months, the Swiss pharmaceutical giant Novartis announced that the British National Institute for Health and Clinical Excellence (NICE) reached an agreement to cooperate together in the United Kingdom to conduct a New Drugs Phase study. In the process, NICE will research the clinical efficiency and evidence-based health economics research to provide technical support.
British health system as an integral part of, NICE's primary function was to prevent British citizens, develop guidelines for treatment of disease. In the past years, NICE has successfully listed a series of new drugs has made a key economic value of clinical evaluation, and therefore its influence to the world from the United Kingdom. As a result, Novartis hopes to NICE clinical studies provide reliable evidence and get their support, thereby accelerating the internal decision-making process of NICE. In the past, NICE has just listed a new product research usually takes two years or so.
In the industry observers, the current cooperation between health care organizations must increase the efficiency. August 2006, on behalf of the United States a top ten pharmaceutical companies invest in the UK pharmaceutical associations put forward their own view that the UK NICE clinical experts and institutions in the earlier period should be research on new drugs to speed up the research results introduced. There is no doubt that the Novartis practicing at this first step.
Aspect In the past 50 years, medical advances have triggered clinical needs, resulting in substantial medical costs of chronic disease, rising health care costs were actually paid (Government Health Insurance Institutions, commercial health insurance companies) do Jiaokubudie. In response to this situation, the health system on new medical technologies and treatments can not only evaluate the safety and efficacy positioned above the point of view of economics need to assess all aspects, and treatment of NICE guidance is also fully the use of this criterion. Novartis and NICE's consideration of this cooperation is the development of new drugs early on concerned about the economics of the problem, large pharmaceutical giants from new drug development process will not boast of its value against the outside world.
Treatment fails? Medicare does not pay!
In Europe, the United Kingdom is one of the most typical state universal health insurance. British health system under the National Health Service (NHS) in charge of the huge government budget, to protect every British citizen's health care expenditure needs. Last year, when the NHS refused to Johnson & Johnson's leukemia treatment drug VELCADE foot the bill when Johnson was forced to make an almost unprecedented proposal?? NHS only through blood tests for those patients proved to be effective for medical expenses. If the treatment proves ineffective, J & J will bear all costs of the patient. It is reported that the blood tests, including the entire medical process of the highest spending may reach 2.4 million.
This is indeed an unusual event. In the past, pharmaceutical companies and government healthcare agencies are often in drug prices, the proportion of total pay, or a temporary problem of drug discount bargain, and pharmaceutical companies to ensure effective practice can be said is a first. Under the pressure of such a guarantee, Johnson & Johnson will have to bear a huge responsibility, was forced to conduct further clinical research to improve drug efficacy and reduce potential risks.
Aspect
Johnson tug of war with the NHS cancer treatment the first time the huge risks passed on to pharmaceutical companies. In the UK, oncology compound annual growth rate of 19%, and therefore the total market from 500 million U.S. dollars in 2002 to expand to 1.5 billion in 2007.
